Cited by

• Evaluation of proinflammatory cytokines and inflammation markers as biomarkers for the action of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers.

  van Doorn M, Kemme M, Ouwens M, van Hoogdalem EJ, Jones R, Romijn H, de Kam M, Schoemaker R, Burggraaf K, Cohen A. van Doorn M, et al. Br J Clin Pharmacol. 2006 Oct;62(4):391-402. doi: 10.1111/j.1365-2125.2005.02532.x. Br J Clin Pharmacol. 2006. PMID: 16995860 Free PMC article. Clinical Trial.
• Activation of peroxisome proliferator-activated receptor-β/-δ (PPAR-β/-δ) ameliorates insulin signaling and reduces SOCS3 levels by inhibiting STAT3 in interleukin-6-stimulated adipocytes.

  Serrano-Marco L, Rodríguez-Calvo R, El Kochairi I, Palomer X, Michalik L, Wahli W, Vázquez-Carrera M. Serrano-Marco L, et al. Diabetes. 2011 Jul;60(7):1990-9. doi: 10.2337/db10-0704. Epub 2011 May 26. Diabetes. 2011. PMID: 21617181 Free PMC article.
• High incidence of glucose intolerance in Vogt-Koyanagi-Harada disease.

  Yawata N, Nakamura S, Kijima M, Ikai N, Kanai M, Sugita M, Ohno S. Yawata N, et al. Br J Ophthalmol. 1999 Jan;83(1):39-42. doi: 10.1136/bjo.83.1.39. Br J Ophthalmol. 1999. PMID: 10209432 Free PMC article.
• Macrophage cholesterol homeostasis and metabolic diseases: critical role of cholesteryl ester mobilization.

  Ghosh S. Ghosh S. Expert Rev Cardiovasc Ther. 2011 Mar;9(3):329-40. doi: 10.1586/erc.11.16. Expert Rev Cardiovasc Ther. 2011. PMID: 21438812 Free PMC article. Review.
• The peroxisome proliferator-activated receptor (PPAR) β/δ agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells.

  Serrano-Marco L, Barroso E, El Kochairi I, Palomer X, Michalik L, Wahli W, Vázquez-Carrera M. Serrano-Marco L, et al. Diabetologia. 2012 Mar;55(3):743-51. doi: 10.1007/s00125-011-2401-4. Epub 2011 Dec 17. Diabetologia. 2012. PMID: 22179221